(p for non-inferiority < 0.001)

Slides:

Advertisements

Similar presentations

ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,

Advertisements

MAIN-COMPARE Study Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease.

Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.

Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.

EXAMINATION Objective Assess the safety and performance of a new-generation DES vs. a BMS in the setting of primary PCI for treatment of patients with.

Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.

TAXUS ATLAS Trial Presented at The EuroPCR meeting Paris, France May 2006 Presented by Dr. Mark Turco TAXUS ATLAS 9-Month Results: Evaluation of TAXUS.

Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.

RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.

(p for noninferiority = 0.01)

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,

Harvard Clinical Research Institute, Boston, US

The BVS-SAVE Italian registry: Bioresorbable Vascular Scaffolds

on behalf of the ABSORB II Investigators

The MASS-DAC Study.

NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

ABSORB Japan: 3-year Clinical and Angiographic Results of a Randomized trial Evaluating the Absorb Bioresorbable Vascular Scaffold vs. Metallic Drug-eluting.

LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.

On behalf of all principal COMPARE II investigators:

Figure 1 Principal degradation characteristics of CE-marked bioresorbable scaffolds. For each device data are shown, where available, for radial support.

TCT 2016, Washington convention center

on behalf of the ABSORB II Investigators

on behalf of the ABSORB II Investigators

Stenting of Coronary Arteries in Non Stress/Benestent Disease

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.

TAXUS II and IV: two-year follow-up

Primary endpoint at 1 year

EXCEL Trial design: Patients with unprotected left main disease were randomized to either PCI with an Xience everolimus-eluting stent (EES) or CABG. They.

American College of Cardiology Presented by Dr. Stephan Windecker

OptiLink HF Trial design: Patients with heart failure who underwent implantation of an ICD were randomized to telemonitoring (n = 505) vs. usual care (n.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

PRECISION Trial design: Patients with arthritis and increased cardiovascular risk were randomized to celecoxib 100 mg twice daily (n = 8,072) vs. ibuprofen.

Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year.

REALITY: 8 month results

ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

EXCITE ISR Trial design: Participants with femoropopliteal in-stent restenosis were randomized to excimer laser atherectomy + adjunctive angioplasty (n.

TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.

EVERBIO II Trial design: Patients with CAD were randomized in a 1:1:1 fashion to either Absorb BVS, Biomatrix Flex stent [BES], or Promus Element EES.

LATITUDE-TIMI 60 Trial design: Patients hospitalized with AMI on guideline-recommended therapy were randomized in a 1:1 fashion to either losmapimod 7.5.

BASKET-SAVAGE Trial design: Patients with a SVG lesion were randomized to a DES (Taxus Liberte; n = 89) versus a BMS (Liberte; n = 84). All patients were.

Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.

BASKET-PROVE II Trial design: Subjects with stable or unstable coronary artery disease undergoing stent implantation were randomized to a biodegradable-polymer.

ISAR-SAFE Trial design: Patients with DES PCI received 6 months of open-label DAPT with aspirin and clopidogrel. At 6 months, they were randomized in a.

Presented at ACC 2003 Late Breaking Clinical Trials

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

The American College of Cardiology Presented by Dr. Raimund Erbel

ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.

ALBATROSS Trial design: Patients with MI without heart failure were randomized to an IV bolus of potassium canrenoate 200 mg as early as possible, then.

After Eighty Study Trial design: Elderly patients with non–ST-elevation acute coronary syndrome (NSTE-ACS) were randomized to invasive therapy (n = 229)

(p = 0.32 for noninferiority)

Drug-eluting stents for in-stent restenosis

(p < for noninferiority)

Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.

(p = for noninferiority)

ACCELERATE Trial design: Patients at high vascular risk were randomized to either evacetrapib 130 mg daily or placebo. They were followed for 30 months.

Ischemic Postconditioning

ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

Primary safety endpoint

OPTIDUAL Trial design: Patients who received a drug-eluting stent and were event-free at 12 months were randomized to an additional 36 months of DAPT with.

Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial

MOMENTUM 3 Trial design: Patients with advanced heart failure were randomized to a centrifugal-flow pump (n = 152) vs. an axial-flow pump (n = 142). Results.

IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.

NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.

Presentation transcript:

(p for non-inferiority < 0.001) ABSORB STEMI TROFI II Trial design: Patients with STEMI were randomized, after partial establishment of coronary flow, to an everolimus-eluting bioresorbable vascular scaffold (BVS) (n = 95) vs. an everolimus-eluting metal stent (n = 96). (p for non-inferiority < 0.001) Results Healing score at 6 months: 1.74 in the BVS group vs. 2.80 in the metal stent group (p for noninferiority < 0.001, p for superiority = 0.053) CV death, MI, or revascularization: 1.1% in the BVS group vs. 0% in the metal stent group The one event in the BVS group was due to stent thrombosis 2.80 1.74 Conclusions Among individuals with STEMI, implantation of a BVS resulted in nearly complete vessel healing, which was noninferior to the everolimus-eluting metal stent Metal stent group BVS Presented by Dr. Patrick Serruys at ESC 2015